Difference between revisions of "Teniposide (Vumon)"
m (→References) |
m |
||
| Line 9: | Line 9: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| − | *[[ | + | *[[B-cell acute lymphoblastic leukemia]] |
| − | *[[ | + | *[[Burkitt lymphoma]] |
*[[Central nervous system (CNS) cancer]] | *[[Central nervous system (CNS) cancer]] | ||
*[[HIV-associated lymphoma]] | *[[HIV-associated lymphoma]] | ||
| Line 32: | Line 32: | ||
[[Category:Topoisomerase inhibitors]] | [[Category:Topoisomerase inhibitors]] | ||
| − | [[Category: | + | [[Category:B-cell acute lymphoblastic leukemia medications]] |
| − | [[Category: | + | [[Category:Burkitt lymphoma medications]] |
[[Category:Central nervous system (CNS) cancer medications]] | [[Category:Central nervous system (CNS) cancer medications]] | ||
[[Category:HIV-associated lymphoma medications]] | [[Category:HIV-associated lymphoma medications]] | ||
Revision as of 01:30, 20 July 2017
Also known as VM-26.
General information
Class/mechanism: Topoisomerase II inhibitor. Teniposide inhibits type II topoisomerase, which results in single and double-stranded DNA breaks and DNA-protein crosslinks. It is cell-cycle specific, acting in late S or early G2, preventing cells from entering mitosis. It is dissolved in Cremophor EL (polyoxyethylated castor oil), which may cause hypersensitivity infusion reactions.[1][2]
Route: IV
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- B-cell acute lymphoblastic leukemia
- Burkitt lymphoma
- Central nervous system (CNS) cancer
- HIV-associated lymphoma
- Small cell lung cancer
Patient drug information
- Teniposide (Vumon) patient drug information (Chemocare)[3]
- Teniposide (Vumon) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 7/14/1992: Initial FDA approval
References
- Drug index
- Chemotherapy
- Intravenous chemotherapy
- Irritant chemotherapy
- Topoisomerase inhibitors
- B-cell acute lymphoblastic leukemia medications
- Burkitt lymphoma medications
- Central nervous system (CNS) cancer medications
- HIV-associated lymphoma medications
- Small cell lung cancer medications
- Drugs FDA approved in 1992